Trial reportBMJ open ophthalmology2025
Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine for myopia control: a randomised trial in children from Central Europe.
Trial report in BMJ open ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe global increase in childhood myopia underscores the need for effective control strategies. This study compares the effectiveness of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine eye drops in slowing myopia progression in European children. This report summarises 1-year outcomes from an ongoing 2-year clinical trial.
methodsA total of 110 Polish children aged 6-16 years, without significant ocular pathology, were randomly assigned to two groups. Group A received single-vision spectacles plus nightly 0.01% atropine drops; group B received DIMS spectacle lenses plus nightly placebo drops. Primary outcomes were changes in cycloplegic spherical equivalent refraction (SER) and axial length, measured every 6 months.
resultsAfter 12 months, mean axial elongation was 0.19±0.03 mm in group A and 0.11±0.02 mm in group B. Among 6-11-year olds, group A showed greater elongation (0.30±0.05 mm) than group B (0.15±0.02 mm). For 12-16-year olds, axial elongation was 0.10±0.02 mm in group A and 0.07±0.02 mm in group B. Mean SER progression was 0.37±0.06 D in group A and 0.23±0.05 D in group B. In the younger group (6-11 years), SER progression was higher in group A (0.60±0.1 D) than group B (0.25±0.05 D). Among older children (12-16 years), SER changes were similar between groups (0.19±0.05 D vs 0.21±0.08 D).
conclusionDIMS spectacle lenses demonstrated superior efficacy to the 0.01% atropine in controlling myopia progression in this cohort, particularly among children aged 6-11 years. These findings support DIMS lenses as an effective intervention for myopia control in Caucasian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.